Christopher Scott Hill - Dec 31, 2024 Form 4 Insider Report for Core Laboratories Inc. /DE/ (CLB)

Role
SVP & CFO
Signature
/s/ Mark Tattoli, Attorney-in-Fact
Stock symbol
CLB
Transactions as of
Dec 31, 2024
Transactions value $
-$254,786
Form type
4
Date filed
1/3/2025, 04:59 PM
Previous filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLB Common Stock Tax liability -$255K -14.7K -15.39% $17.31 80.9K Dec 31, 2024 Direct
transaction CLB Common Stock Options Exercise $0 +23.6K +32.77% $0.00 95.7K Dec 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLB Performance Shares Options Exercise $0 -23.6K -100% $0.00 0 Dec 31, 2024 Common Stock 23.6K $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were awarded as restricted performance shares in February 2022, as disclosed in the Reporting Person's Form 4 filing on February 17, 2022. The Company finished in the 52nd percentile of return on invested capital among the Bloomberg Peer Group at the conclusion of the performance period on December 31, 2024. Therefore, the performance criteria and requirements for vesting have been satisfied at 54.6% of the target award level, and such number of shares vested on December 31, 2024.